Dexcom (Nasdaq: DXCM), a San Diego-based continuous glucose monitoring manufacturer, is taking a 216,000-square-foot building on South Dobson Road near Loop 101 in Mesa’s Fiesta District.
Source: Phoenix Business Journal Eric Jay Toll
Medical Device and Diagnostics Industry (blog)-May 26, 2016
Back in August 2015, continuous glucose monitoring firm Dexcom announced that it would be partnering with Verily, formerly Google Life ...
Qualcomm teams with Medtronic on glucose monitors
In-Depth-The San Diego Union-Tribune-May 25, 2016
In-Depth-The San Diego Union-Tribune-May 25, 2016
Explore in depth (26 more articles)
DexCom, Inc. (NASDAQ:DXCM)‘s stock had its “outperform” rating reaffirmed by investment analysts at Wedbush in a research note issued on Wednesday. They currently have a $112.00 price objective on the medical device company’s stock. Wedbush’s price target would suggest a potential upside of 52.59% from the company’s current price.
DexCom (NASDAQ:DXCM) opened at 73.40 on Wednesday. DexCom has a one year low of $47.92 and a one year high of $103.29. The company’s market capitalization is $6.12 billion. The company’s 50-day moving average is $65.47 and its 200 day moving average is $69.38. 
Other large investors recently bought and sold shares of the company. Janus Capital Management bought a new stake in DexCom during the third quarter worth $8,500,000. Shaker Investments LLC OH increased its position in shares of DexCom by 2.8% in the fourth quarter. Shaker Investments LLC
A number of other analysts have also recently issued reports on DXCM. Jefferies Group raised their price objective on DexCom from $90.00 to $100.00 and gave the company a “buy” rating in a research report on Wednesday, February 24th. Leerink Swann dropped their price target on DexCom from $100.00 to $90.00 in a research note on Friday, February 26th. JPMorgan Chase & Co. reaffirmed an “overweight” rating and set a $100.00 price target (down previously from $120.00) on shares of DexCom in a report on Wednesday, February 24th. Canaccord Genuity reaffirmed a “buy” rating on shares of DexCom in a research report on Thursday, April 28th. Finally, Robert W. Baird reiterated a “hold” rating on shares of DexCom in a report on Monday, May 16th. Three equities research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $94.09.
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers for the treatment of people with and without diabetes. Its products include SEVEN PLUS, DexCom G4, DexCom G4 PLATINUM, DexCom Share System and DexCom G5 Mobile.
Remarks from this online interview
MDO: Obviously, Medtronic is also a competitor in the CGM space. What is your strategy for competing with large, established players like them in this space?
There were times in Dexcom’s history that were extremely challenging. Back in late 2008, the markets had turned very bad. We were struggling as a company. We had introduced the Seven Plus CGM system, but we were running out of money. A large shareholder had to dump 3 million shares of our stock in a few days. As a result the share price plummeted to $1.39. Luckily, I had the wherewithal to step in and buy a significant number of shares in the open market to indicate my confidence in the company. Today, we trade at $50.00 a share, but there were very lean times.
However, we never lost our mission view. I never told anyone how dire our situation was — only a handful of people, including the board, knew. But we rallied. I said, “I’ll figure out a way to get us money.” That pit bull mentality is critical. Once you latch on to something, don’t let go. You’ll find a way. It may be tough, but you’ll find a way.
Gregg: The biggest challenge I see in front of us is a very rapidly changing healthcare landscape. Under the Accountable Care Act and other activities, you can see the writing on the wall for physicians — they are going to get paid for performance. I think the medical device industry is slightly behind that revolution in the way healthcare is delivered...you will certainly see us move back into the hospital arena with a subcutaneous sensor
The sad thing right now is that there are 64-year-olds with private insurance who have had great success managing their diabetes with CGM, but they are facing the loss of reimbursement coverage as they migrate to Medicare. Dexcom is working on some initiatives to create opportunities for those truly needy patients. If they don’t have coverage, we will try to figure out something that can help them financially to acquire the product. For example, we have created a foundation that employees — including Dexcom executives — will spend their money to populate. It will be launched in the first part of 2015
No comments:
Post a Comment